# US 6,730,677 B2 · Benzofurazan compounds which enhance AMPA receptor activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,677 B2
- Document ID: US6730677B2
- Status: Granted
- Kind: B2
- Application number: 09/845,128
- Filed: 2001-04-27
- Published: 2002-05-09
- Granted: 2004-05-04
- Earliest claimed: 1997-02-13
- Assignees: The Regents of the University of California
- Inventors: Gary A. Rogers; Christopher M. Marrs
- Web page: https://patentgrep.com/patent/US6730677B2

## CPC

- C07D 285/14: condensed with carbocyclic rings or ring systems
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/53: having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495})
- A61P 5/00: Drugs for disorders of the endocrine system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 271/12: condensed with carbocyclic rings or ring systems
- C07D 413/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds of general structural formula (1) are shown to have AMPA receptor enhancing properties. The compounds are useful for such therapeutic purposes as facilitating the learning of behaviors dependent upon AMPA receptors, and in treating conditions, such as memory impairment, in which AMPA receptors, or synapses utilizing these receptors, are reduced in numbers or efficiency. They may also be used to enhance excitatory synaptic activity in order to restore an imbalance between brain subregions, as in treatment of schizophrenia or schizophreniform behavior.

## Claims

### Claim 1

A compound having the structure:
in which:
R1 is oxygen or sulfur;
R2 and R3 are independently selected from the group consisting of —CR═ and —CX═;
M is ═CR4, wherein R4 and R8 are independently R or together form a single linking moiety linking M to the ring vertex 2′, the linking moiety being selected from the group consisting of a single bond, —CRR′—, —CR═CR′—, —C(O)—, —S(O)y—, —NR—, and —N═; and
R5 and R7 are independently selected from the group consisting of —(CRR′)n—, —C(O)—, —CR═CR′—, —CR═CX—, —CRX—, —CXX′—, —S—, and —O—, and
R6 is selected from the group consisting of —(CRR′)m—, —C(O)—, —CR═CR′—, —CRX—, —CXX′—, —S—, and —O—;
wherein
X and X′ are independently selected from —Br, —Cl, —F, —CN, —NO2, —OR, —SR, —NRR′, —C(O)R, —CO2R, or —CONRR′, wherein two groups R or R′ on an individual group X, or on two adjacent groups X, may together form a ring; and
R and R′ are independently selected from (i) hydrogen, (ii) C1-C6 branched or unbranched alkyl or C3 to C6 cycloalkyl groups, which may be unsubstituted or substituted with one: or more functionalities selected from halogen, nitro, alkoxy, hydroxy, alkylthio, amino, keto, aldehyde, carboxylic acid, carboxylic ester, or carboxylic amide, and wherein two such alkyl groups on a single carbon or on adjacent carbons may together form a ring, and (iii) aryl, which may be unsubstituted or substituted with one or more functionalities selected from halogen, intro, alkoxy, hydroxy, aryloxy, alklcylthio, amino, keto, aldehyde, carboxylic acid, carboxylic ester, or carboxylic amide;
m and p are, independently, 0 or 1; and
n and y are, independently, 0, 1 or 2.

### Claim 2 (depends on 1)

A compound in accordance with claim 1 in which R and R′ are independently selected from (i) hydrogen and (ii) C1-C6 branched or unbranched alkyl or C3 to C6 cycloalkyl, which may be unsubstituted or substituted with one or more functionalities selected from halogen, nitro, alkoxy, hydroxy, alkylthio, amino, keto, aldehyde, carboxylic acid, carboxylic ester, or carboxylic amide, and wherein two such alkyl groups on a single carbon or on adjacent carbons may together form a ring.

### Claim 3 (depends on 1)

A compound in accordance with claim 1 in which R2 and R3 are —CR═.

### Claim 4 (depends on 3)

A compound in accordance with claim 3 in which p is 0 and R4 and R8 are hydrogen.

### Claim 5 (depends on 4)

A compound in accordance with claim 4 in which R5 and R7 are —(CRR′)n— and R6 is —(CRR′)m—.

### Claim 6 (depends on 3)

A compound in accordance with claim 3 in which p is 0, R4, R8, R, and R′ are hydrogen, and m=n=1.

### Claim 7 (depends on 4)

A compound in accordance with claim 4 in which R5 is —CR═CX—, R6 is —(CRR′)m—, R7 is —(CRR′)n—, and m is 0.

### Claim 8 (depends on 7)

A compound in accordance with claim 7 in which R and R′ are hydrogen.

### Claim 9 (depends on 8)

A compound in accordance with claim 8 in which X is fluorine and n is 1, said compound being 1-(benzofurazan-5-ylcarbonyl)-4-fluoro-1,2,3,6-tetrahydropyridine.

### Claim 10 (depends on 4)

A compound in accordance with claim 4 in which R5 is —CR═CR′—, R6 is —(CRR′)m—, R7 is —(CRR′)n—, and m is 0.

### Claim 11 (depends on 10)

A compound in accordance with claim 10 in which R and R′ are hydrogen.

### Claim 12 (depends on 11)

A compound in accordance with claim 11 in which n is 1, said compound being 1-(benzofurazan-5-ylcarbonyl)-1,2,3,6-tetrahydropyridine.

### Claim 13 (depends on 4)

A compound in accordance with claim 4 in which R5 and R7 are —(CRR′)n—, and R6 is —C(O)—, —CRX—, CXX′—, —O—, or —S—.

### Claim 14 (depends on 13)

A compound in accordance with claim 13 in which R6 is —CXX′—, R and R′ are hydrogen, n is 1, and X and X′ are fluorine, said compound being 1-(benzofurazan-5-ylcarbonyl)-4′,4′-difluoropiperidine.

### Claim 15 (depends on 13)

A compound in accordance with claim 13 in which which R6 is —CRX′—, R and R′ are hydrogen, and n is 1.

### Claim 16 (depends on 13)

A compound in accordance with claim 13 in which R6 is —S—, or —C(O)—, n is 1, and R and R′ are hydrogen, said compound being selected from 4-(benzofurazan-5-ylcarbonyl)thiomorpholine, and 4-(benzofurazan-5-ylcarbonyl)-4-piperidone.

### Claim 17 (depends on 1)

A compound in accordance with claim 1 wherein R4 and R8 together form a single linking moiety linking M to the ring vertex 2′, the linking moiety being a single bond, —CRR′—, —CR═CR′—, —C(O)—, —S—, —NR—, or —N═.

### Claim 18 (depends on 17)

A compound in accordance with claim 17 in which R2 and R3 are —CR═.

### Claim 19 (depends on 18)

A compound in accordance with claim 18 in which p is 0, R5 and R7 are —(CRR′)n—, and R6 is —(CRR′)m—.

### Claim 20 (depends on 19)

A compound in accordance with claim 19 in which n=1.

### Claim 21 (depends on 19)

A compound in accordance with claim 19 in which the linking moiety is —CRR′—, —S—, or —N═.

### Claim 22 (depends on 21)

A compound in accordance with claim 21 in which the linking moiety is —S— or —N═.

### Claim 23 (depends on 1)

A compound in accordance with claim 1 in which R6 is selected from the group consisting of —(CRR′)m—, —C(O)—, —CR═CR′—, —CRX—, —CXX′—, and —S—, and R and R′ are independently selected from C1-C7 branched or unbranched alkyl or C3 to C6 cycloalkyl, which may be unsubstituted or substituted with one or more functionalities selected from halogen, nitro, alkoxy, hydroxy, alkylthio, amino, keto, aldehyde, carboxylic acid, carboxylic ester, or carboxylic amide, and wherein two such alkyl groups on a single carbon or on adjacent carbons may together form a ring.

### Claim 24 (depends on 1)

A compound in accordance with claim 1 chosen from the from the group consisting of:
a. 1-(benzo-2,1,3-thiadiazole-5-ylcarbonyl)piperidine
b. 1-(benzofurazan-5-ylcarbonyl)-4-fluoro-1,2,3,6-tetrahydropyridine
c. 1-(benzofurazan-5-ylcarbonyl)-1,2,3,6-tetrahydropyridine
d. 1-(benzofurazan-5-ylcarbonyl)-4′,4′-difluoropiperidine
e. 4-(benzofurazan-5-ylcarbonyl)thiomorpholine
f. 4-(benzofurazan-5-ylcarbonyl)-4-piperidone.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

A method for enhancing AMPA receptor function in a mammalian subject in need thereof, said method comprising administering to said subject a compound in accordance with any of claims 1-22, 23 or 24, in a pharmaceutically acceptable carrier.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

A method for enhancing AMPA receptor function in a mammalian subject in need thereof, wherein said enhancing is effective to alleviate impairment of memory or other cognitive functions caused by a hypoglutamatergic condition or by deficiency in the number or strength of excitatory synapses or in the number of AMPA receptors, said method comprising administering to said subject a compound in accordance with any of claims 1-22, 23 or 24, in a pharmaceutically acceptable carrier.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

A method for enhancing AMPA receptor function in a mammalian subject in need thereof, wherein said enhancing is effective to treat schizophrenia or schizophreniform behavior, said method comprising administering to said subject a compound in accordance with any of claims 1-22, 23 or 24, in a pharmaceutically acceptable carrier.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

A method for enhancing AMPA receptor function in a mammalian subject in need thereof, wherein said enhancing is effective to facilitate learning of behaviors dependent on AMPA receptor functioning, said method comprising administering to said subject a compound in accordance with any of claims 1-22, 23 or 24, in a pharmaceutically acceptable carrier.

### Claim 29

A method for enhancing AMPA receptor function in a mammalian subject in need thereof, said method comprising administering to said subject a compound selected from the group consisting of:
a. 1-(benzo-2,1,3-thiadiazole-5-ylcarbonyl)piperidine
b. 1-(benzofurazan-5-ylcarbonyl)-4-fluoro-1,2,3,6-tetrahydropyridine
c. 1-(benzofurazan-5-ylcarbonyl)-1,2,3,6-tetrahydropyridine
d. 1-(benzofurazan-5-ylcarbonyl)-4′,4′-difluoropiperidine
e. 4-(benzofurazan-5-ylcarbonyl)thiomorpholine
f. 4-(benzofurazan-5-ylcarbonyl)-4-piperidone
in a pharmaceutically acceptable carrier.
